Beam Therapeutics

BEAM

Market cap $2.89B

Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior efficacy in sickle cell disease, but commercial success hinges on overcoming conditioning protocol challenges and competing with Vertex/Crispr's head start. The liver-targeted BEAM-302 program demonstrates strong early clinical results and could establish a competitive moat, with pivotal data and BLA submission expected in 18–24 months.

Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.

Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript

Beam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectations of $12.567 million.

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago.

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD) CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD).

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

Bethany J. Cavanagh sold 6,198 direct shares for a transaction value of approximately $216,933 at a weighted average price of around $35.00 per share. The sale represented 15.11% of direct post-transaction holdings, reducing direct ownership from 41,011 to 34,813 shares.

Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript